TaperCommunityTaperCommunity
Forums/Drug Profiles/

Lexapro

escitalopram

SSRIFDA 2002
Go to Community Forum

Boxed Warning

Suicidality risk in children, adolescents, and young adults under 25 during initial treatment.

Overview

Escitalopram is the therapeutically active S-enantiomer of citalopram, an SSRI used for the treatment of major depressive disorder and generalized anxiety disorder. It is considered one of the most selective SSRIs available.

Common Doses

5mg, 10mg, 20mg

Formulations

Tablets: 5mg, 10mg, 20mg; Oral solution: 1mg/mL

Pregnancy

Category C (risk cannot be ruled out)

Mechanism of Action

Selective serotonin reuptake inhibitor (SSRI) that binds with high affinity to the serotonin transporter (SERT), blocking reuptake of serotonin into the presynaptic neuron and increasing serotonergic neurotransmission.

Taper Notes

Hyperbolic taper recommended. Liquid formulation (1mg/mL) available for precise final cuts below 5mg.

Maudsley Deprescribing Guidance

Reduce by proportionally smaller amounts at lower doses. Final reductions (2.5mg → 0) are often the hardest. Consider liquid formulation for cuts below 2.5mg.

Common Withdrawal Symptoms

brain zapsdizzinessinsomniairritabilitynauseaemotional blunting

Interactions & Safety

Drug Interactions

  • MAOIs — contraindicated (risk of serotonin syndrome)
  • CYP2C19 inhibitors (e.g., omeprazole) may increase escitalopram levels
  • Serotonergic drugs (triptans, tramadol, St. John's Wort) increase serotonin syndrome risk

Food Interactions

  • Grapefruit juice may increase levels via CYP3A4 inhibition
  • No significant food effect on absorption

Contraindications

  • MAOIs within 14 days
  • Pimozide
  • Known hypersensitivity to escitalopram or citalopram

Toxicity

Serotonin syndrome at high doses or in combination with serotonergic agents. QT prolongation rare but dose-dependent.

Pharmacokinetics

ADME Profile

Absorption

Rapidly absorbed after oral administration, Tmax ~5 hours, bioavailability ~80%, unaffected by food.

Distribution

~12 L/kg

Metabolism

Hepatic via CYP3A4 and CYP2C19 to S-demethylcitalopram (S-DCT) and S-didemethylcitalopram (S-DDCT), both with minimal pharmacological activity.

Elimination

Renal (~8% excreted unchanged) and hepatic metabolism.

Protein Binding

~56%

Clearance

~600 mL/min (oral clearance)

Need a clinician who understands tapering?

Browse our map of deprescribing-informed providers worldwide.

Find a Deprescriber

Other Drug Profiles